Noting how difficult it can be for investors to understand what’s happening in the biotech industry generally and at specific biotech companies, the author of today’s article explains that he tends to invest “in companies that have a track record of working with existing products while successfully developing pipelines of new products” and in “picks-and-shovels companies that get paid to sell their products and services to the developers” – and he proceeds to highlight five of his “rational” biotech picks to consider. For more, CLICK HERE.
